Division of Pfizer Inc.
Latest From Wyeth Pharmaceuticals
Evenity's Postmarketing Requirement Includes Feasibility Component Familiar To Other Osteoporosis Drugs
Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.
Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in immuno-oncology and by most accounts is the highlight of the pharma's "string of pearls" strategy.
The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.
- Therapeutic Areas
- Wyeth-Ayerst Laboratories
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Joseph M Mahady, Pres.
Mark Lee, PhD, SVP, Bus. Dev., Pharma & Head, Worldwide Licensing
Gary L Stiles, MD, EVP, CMO
Geno Germano, Pres., US & Gen. Manager
- Contact Info
Phone: (610) 902-1200
500 Arcola Rd.
Collegeville, PA 19426
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.